Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech. Agenus revealed BMS' decision ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2827.05. The stock has experienced fluctuations ...

• Corporate actions are actions taken by a company that impact the shareholders’ value directly. It is an event that brings material changes to a company and affects its stakeholders ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

8th May 2025 7:00 am RNS Transaction in Own Shares ...

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...